Reductions in A1C from baseline (%)1
ap<0.05 for superiority vs Ozempic 1 mg, adjusted for multiplicity.
bp<0.001 for superiority vs Ozempic 1 mg, adjusted for multiplicity.
Bar chart depicting A1C change from baseline at 40 weeks. There were 470, 469, 469, and 468 patients in the Mounjaro 5 mg, 10 mg, 15 mg, and Ozempic 1 mg treatment groups, respectively, and each treatment group had a mean baseline A1C of 8.3%. Mean change in A1C at 40 weeks was - 2.0% (p<0.05 for superiority vs. Ozempic, adjusted for multiplicity), -2.2% (p<0.001 for superiority vs. Ozempic, adjusted for multiplicity), -2.3% (p<0.001 for superiority vs. Ozempic, adjusted for multiplicity), and -1.9% for Mounjaro 5 mg, 10 mg, 15 mg, and Ozempic 1 mg, respectively